BWA
ALDX icon

Basecamp Wealth Advisors’s Aldeyra Therapeutics ALDX Stock Holding History

Basecamp Wealth Advisors’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-109
Closed -$184 – 1824
2026
Q1 		$184 Buy
+109
New +$478 ﹤0.01% 1875

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Basecamp Wealth Advisors's ALDX Position: Q2 2026 in Review

Basecamp Wealth Advisors sold out of Aldeyra Therapeutics (ALDX) in Q2 2026, closing a stake of 109 shares — an estimated $184 sold.

Basecamp Wealth Advisors first reported a position in ALDX in Q1 2026 and held it in 1 quarter. The position peaked at $184 in Q1 2026. 108 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

  • Basecamp Wealth Advisors reported no remaining Aldeyra Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Basecamp Wealth Advisors sold 109 Aldeyra Therapeutics shares in Q2 2026, an estimated $184.
  • Basecamp Wealth Advisors first reported a position in Aldeyra Therapeutics in Q1 2026 and held it in 1 quarter.
  • Basecamp Wealth Advisors's Aldeyra Therapeutics position peaked at $184 in Q1 2026.
  • 108 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.